Kristi McIntyre, MD, a physician with Texas Oncology, discusses the results of a phase II, multicenter, single-arm study that studies eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer.

McIntyre says the overall response rate (ORR) of the trial was 29% but the clinical benefit rate, which was CR, PR and stable disease, was 52%.

Eribulin is a non-taxane, McIntyre explains, but it also targets the microtubule as a taxane would. Eribulin is given IV on day 1 and 8 of a 28-day cycle. McIntyre says the treatment lasts only 2-5 minutes and does not have hypersensitivity reactions like taxanes.

This treatment, McIntyre says, compares favorably to other first-line agents in metastatic breast cancer. The study contained both triple-negative and hormone positive breast cancer patients and all of the metastatic breast cancer patients that participated were HER2-negative.

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Breast Cancer

 Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

San Antonio Breast Cancer Symposium

Kristi McIntyre, MD, from Texas Oncology, discusses the results of a phase II, multicenter, single-arm study that studies eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer.

Dr. McIntyre on Frontline Eribulin in HER2-Negative MBC